25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1

Author： Amir Eitan   Cecchini Reena   Ganz Patricia   Costantino Joseph   Beddows Samantha   Hood Nicola   Goodwin Pamela  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.133, Iss.3, 2012-06, pp. : 1077-1088

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen

By Billgren A.-M.   Rutqvist L.E.   Johansson H.   Hagerstrom T.   Skoog L.  

European Journal of Cancer, Vol. 36, Iss. 11, 2000-07 ,pp. : 1374-1380

Elsevier

Access to resources Recommend Favorite

Associations between vitamin D receptor polymorphisms and breast cancer risk

By Wang Jie   He Qi   Shao Yu-guo   Ji Min   Bao Wei  

Tumor Biology, Vol. 34, Iss. 6, 2013-12 ,pp. : 3823-3830

Springer Publishing Company

Access to resources Recommend Favorite

Stroke risk and tamoxifen therapy for breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 4, 2004-12 ,pp. : 290-291

Informa Healthcare

Access to resources Recommend Favorite

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

By Azoulay Laurent  

Breast Cancer Research and Treatment, Vol. 126, Iss. 3, 2011-04 ,pp. : 695-703

Springer Publishing Company

Access to resources Recommend Favorite

p16 promoter hypermethylation is associated with increased breast cancer risk

By            

Molecular Medicine Reports, Vol. 6, Iss. 4, 2012-01 ,pp. : 904-908

Spandidos Publications

Access to resources Recommend Favorite